Association of sodium-glucose cotransporter-2 inhibitor use and mortality in patients with endometrial cancer: a retrospective cohort study.

IF 3.4 2区医学 Q2 ONCOLOGY

BMC Cancer Pub Date : 2025-07-01 DOI:10.1186/s12885-025-14453-w

Min Wang, Mingxia Ye, Maria Lucero, Wanchun Pan, Xin Wang, Heping Zhang, Ling Zhou, Yuanguang Meng

{"title":"Association of sodium-glucose cotransporter-2 inhibitor use and mortality in patients with endometrial cancer: a retrospective cohort study.","authors":"Min Wang, Mingxia Ye, Maria Lucero, Wanchun Pan, Xin Wang, Heping Zhang, Ling Zhou, Yuanguang Meng","doi":"10.1186/s12885-025-14453-w","DOIUrl":null,"url":null,"abstract":"Background: Endometrial cancer is closely linked to obesity and type 2 diabetes mellitus (T2DM). Sodium-glucose cotransporter-2 inhibitors (SGLT2i), originally developed for diabetes, demonstrate potential anti-cancer properties. This study aims to investigate the association between SGLT2i use and all-cause mortality among patients with endometrial cancer.Methods: We conducted a real-world, retrospective cohort study using data from the US TriNetX electronic health record database. Female patients diagnosed with endometrial cancer between 2014 and 2023 were included. Propensity score matching (1:1) balanced baseline characteristics, including demographics, comorbidities, and medication use. The primary outcome was overall survival, analyzed via Kaplan-Meier curves and Cox proportional hazards regression.Results: A total of 2,079 matched patient pairs were analyzed (SGLT2i vs. non-SGLT2i). SGLT2i use was significantly associated with lower all-cause mortality (8.21% vs. 20.56%; HR, 0.50; 95% CI, 0.41-0.59; P < 0.0001). Subgroup analyses indicated consistent survival benefits in patients regardless of age and body mass index, and those with heart failure, T2DM, and chronic kidney disease. SGLT2i did not increase risks of serious adverse events, including urinary tract infections, ketoacidosis, sepsis, or acute kidney failure.Conclusions: As one of the treatments for T2DM, SGLT2i treatment in patients with endometrial cancer was associated with significantly reduced all-cause mortality, highlighting its potential as an adjunctive therapeutic strategy.","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1065"},"PeriodicalIF":3.4000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12211756/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12885-025-14453-w","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Endometrial cancer is closely linked to obesity and type 2 diabetes mellitus (T2DM). Sodium-glucose cotransporter-2 inhibitors (SGLT2i), originally developed for diabetes, demonstrate potential anti-cancer properties. This study aims to investigate the association between SGLT2i use and all-cause mortality among patients with endometrial cancer.

Methods: We conducted a real-world, retrospective cohort study using data from the US TriNetX electronic health record database. Female patients diagnosed with endometrial cancer between 2014 and 2023 were included. Propensity score matching (1:1) balanced baseline characteristics, including demographics, comorbidities, and medication use. The primary outcome was overall survival, analyzed via Kaplan-Meier curves and Cox proportional hazards regression.

Results: A total of 2,079 matched patient pairs were analyzed (SGLT2i vs. non-SGLT2i). SGLT2i use was significantly associated with lower all-cause mortality (8.21% vs. 20.56%; HR, 0.50; 95% CI, 0.41-0.59; P < 0.0001). Subgroup analyses indicated consistent survival benefits in patients regardless of age and body mass index, and those with heart failure, T2DM, and chronic kidney disease. SGLT2i did not increase risks of serious adverse events, including urinary tract infections, ketoacidosis, sepsis, or acute kidney failure.

Conclusions: As one of the treatments for T2DM, SGLT2i treatment in patients with endometrial cancer was associated with significantly reduced all-cause mortality, highlighting its potential as an adjunctive therapeutic strategy.

查看原文本刊更多论文

钠-葡萄糖共转运蛋白-2抑制剂的使用与子宫内膜癌患者死亡率的关系：一项回顾性队列研究

背景：子宫内膜癌与肥胖和2型糖尿病（T2DM）密切相关。钠-葡萄糖共转运蛋白-2抑制剂（SGLT2i），最初是为糖尿病开发的，显示出潜在的抗癌特性。本研究旨在探讨子宫内膜癌患者使用SGLT2i与全因死亡率之间的关系。方法：我们使用来自美国TriNetX电子健康记录数据库的数据进行了一项真实世界的回顾性队列研究。研究纳入了2014年至2023年间诊断为子宫内膜癌的女性患者。倾向评分匹配（1:1）平衡基线特征，包括人口统计学、合并症和药物使用。主要终点为总生存率，通过Kaplan-Meier曲线和Cox比例风险回归进行分析。结果：共分析了2079对匹配的患者（SGLT2i与非SGLT2i）。SGLT2i的使用与较低的全因死亡率显著相关(8.21% vs. 20.56%；人力资源,0.50;95% ci, 0.41-0.59；结论：作为T2DM的治疗方法之一，子宫内膜癌患者的SGLT2i治疗与全因死亡率显著降低相关，突出了其作为辅助治疗策略的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMC Cancer 医学-肿瘤学

CiteScore

6.00

自引率

2.60%

发文量

1204

审稿时长

6.8 months

期刊介绍： BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.